

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Avacopan for treating autoanti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

#### Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Vifor Pharma UK (avacopan)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Asthma UK</li> <li>Genetic Alliance UK</li> <li>Kidney Care UK</li> <li>Kidney Research UK</li> <li>Lauren Currie Twilight Foundation</li> <li>Lupus UK</li> <li>National Kidney Federation</li> <li>National Rheumatoid Arthritis Society</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Vasculitis UK</li> <li>Versus Arthritis</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>Association for Respiratory Technology and Physiology</li> <li>Association of Respiratory Nurse Specialists</li> <li>British Association for Paediatric Nephrology</li> <li>British Association of Dermatologists</li> <li>British Association of Urological Nurses</li> <li>British Association of Urological Surgeons</li> <li>British Dermatological Nursing Group</li> <li>British Geriatrics Society</li> <li>British Renal Society</li> <li>British Skin Foundation</li> <li>British Society for Paediatric and Adolescent Rheumatology</li> <li>British Society for Rheumatology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Hospital Information Services – Jehovah’s Witnesses</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association for Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>Accord (methotrexate, mycophenolate, prednisolone)</li> <li>Advanz (methotrexate, prednisolone)</li> <li>Aspen Medical Europe (azathioprine)</li> <li>Baxter Healthcare (cyclophosphamide)</li> <li>Cipla (methotrexate)</li> <li>Ennogen Pharma (azathioprine)</li> </ul>

Final stakeholder list for the single technology appraisal of avacopan for treating autoanti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

Issue date: August 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Thoracic Society</li> <li>• Health Lumen</li> <li>• Immunodeficiency UK</li> <li>• Primary Care Dermatology Society</li> <li>• Primary Care Respiratory Society UK</li> <li>• Primary Care Rheumatology and Musculoskeletal Medicine Society</li> <li>• Renal Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for DGH Nephrologists</li> <li>• Society of Vascular Nurses</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Renal Pharmacy Group</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Blackburn with Darwen CCG</li> <li>• NHS England</li> <li>• NHS Wyre Forest CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Hospira UK (methotrexate)</li> <li>• Logixx Pharma Solutions (prednisolone)</li> <li>• Medac UK (methotrexate)</li> <li>• Morningside healthcare (methotrexate)</li> <li>• Mylan UK (azathioprine, mycophenolate)</li> <li>• Napp Pharmaceuticals (prednisone, rituximab)</li> <li>• Nordic Pharma (methotrexate)</li> <li>• Novartis (mycophenolate)</li> <li>• Orion Pharma (UK) (methotrexate)</li> <li>• Pfizer (methotrexate)</li> <li>• Phoenix Labs (prednisolone)</li> <li>• Roche Products (mycophenolate, cyclophosphamide, rituximab)</li> <li>• Rosemont Pharmaceuticals Limited (methotrexate)</li> <li>• Sandoz (methotrexate, cyclophosphamide, mycophenolate, rituximab)</li> <li>• Teva Pharma (mycophenolate)</li> <li>• Therakind (methotrexate)</li> <li>• Tillomed (mycophenolate, azathioprine)</li> <li>• Wockhardt UK (prednisolone)</li> <li>• Zentiva UK (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Dermatological Surgery</li> <li>• Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group</li> <li>• Cochrane Skin Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Skin Treatment and Research Trust</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.